



[7/19/2022]

Federal Communications Commission  
445 12<sup>th</sup> Street SW  
Washington, DC 20554

Subject: Limited Agency Agreement  
BioSerenity USA, Inc.  
FCC ID: 2A7VI-ACCV3

To Whom It May Concern:


We, BioSerenity USA, Inc., hereby authorized Intertek Testing Services Shenzhen Ltd. Guangzhou Branch to act as our Agent for the purpose of preparing application for FCC ID number 2A7VI-ACCV3 under all applicable parts of the FCC rules and regulations.

The effective date of this limited agency agreement is July 19<sup>th</sup>, 2022. The Limited Agency Agreement expires on January 31<sup>st</sup>, 2023, unless sooner terminated or extended by written notice to Intertek Testing Services Shenzhen Ltd. Guangzhou Branch and the Federal Communications Commission.

This is to advise that we are in full compliance with the Anti-Drug Abuse Act. The applicant is not subject to a denial of federal benefits pursuant to Section 5301 of the Anti-Drug Act of 1988, 21 U.S.C. 862, and no party to the application is subject to a denial of federal benefits pursuant to that section.

If you have any questions or comments, please do not hesitate to contact me.

Sincerely,

DocuSigned by:  
  
20CA4EAC86EB407...

Madubuike OKAFOR  
Director of QMS & Regulatory Affairs for US Medical Devices